OPDIVO 10 mg/mL concentrate for solution for infusion., OPDIVO 10 mg/mL concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion, YERVOY 5 mg/ml concentrate for solution for infusion, LENVIMA 10 mg hard capsules, AXITINIB SANDOZ 5 mg, comprimé pelliculé, CABOMETYX 40 mg film-coated tablets
2023/3764
Phase 3 small_molecule active
Quick answer
OPDIVO 10 mg/mL concentrate for solution for infusion., OPDIVO 10 mg/mL concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion, YERVOY 5 mg/ml concentrate for solution for infusion, LENVIMA 10 mg hard capsules, AXITINIB SANDOZ 5 mg, comprimé pelliculé, CABOMETYX 40 mg film-coated tablets for Metastatic renal cell carcinoma (mRCC) is a Phase 3 program (small_molecule) at Institut für biomedizinische Analytik NMR-Imaging GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Institut für biomedizinische Analytik NMR-Imaging GmbH
- Indication
- Metastatic renal cell carcinoma (mRCC)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active